Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.

Abstract

Since the CB1 receptor antagonist SR141716 (rimonabant) was reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target in the treatment of obesity. Several series of derivatives based on diarylimidazolyl oxadiazole and thiadiazole scaffolds were synthesized and tested for CB1 receptor binding affinity. SAR studies directed toward the optimization of imidazole scaffolds resulted in the discovery of 10s which showed highest potency for CB1 receptor binding affinity (IC(50)=1.91nM) prepared to date.

• Authors: Jong Yup Kim, Hee Jeong Seo, Sung-Han Lee, Myung Eun Jung, Kwangwoo Ahn, Jeongmin Kim, Jinhwa Lee
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 19 Issue 1 Pg. 142-5 (Jan 01 2009) ISSN: 1464-3405 [Electronic] England
• PMID: 19022666 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Imidazoles
• Oxadiazoles
• Receptor, Cannabinoid, CB1
• Thiadiazoles

Topics

• Animals
• Imidazoles
• Inhibitory Concentration 50
• Obesity (drug therapy)
• Oxadiazoles (chemical synthesis, pharmacology)
• Rats
• Receptor, Cannabinoid, CB1 (antagonists & inhibitors)
• Structure-Activity Relationship
• Thiadiazoles (chemical synthesis, pharmacology)